ClinicalTrials.gg
CompletedNCT00316589Updated Jan 3, 2019Results posted

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

A Phase 2 interventional study of IMVAMUNE (MVA-BN) in HIV Infections, sponsored by Bavarian Nordic. Completed at 36 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-03.

Sponsored by Bavarian Nordic · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
581
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
213th of 2,150
581 · median 60
Started
2006
with 108 others
Phase 2
478 of 2,802
7 open now
Registered
1,611th of 2,802
by date

Among the 2,802 studies in HIV Infections with a site in United States, this one is the 213th largest by enrollment of the 2,150 interventional ones that give a count, is one of 109 that started in 2006, is one of 478 in phase 2, and was the 1,611th registered.

HIV Infections

4,736 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,802 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV
  • treatment experienced
  • treatment vaccinia naive
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

  • Genders eligible for Study: Both
  • Age: between 18 and 55 years
  • Healthy volunteers are accepted

Inclusion criteria

Inclusion Criteria:

  • Subjects tested positive for -1 infection (HIV-infected subjects).
  • Subjects that are tested negative for HIV (Healthy subjects).
  • Either on stable antiretroviral therapy or not on antiretroviral therapy.
  • CD4 cells > = 200 - 750/µl.
  • Subjects must be in good general health except for HIV infection.
  • Women must not be pregnant and use an acceptable method of .

Exclusion criteria

Exclusion Criteria:

  • Impairment of immunologic function (other than infection).
  • History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or , uncontrolled high blood pressure.
  • Uncontrolled serious infection.
  • History of or active disease.
  • History or clinical manifestation of and severe hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders.
  • History of an immediate family member (father, mother, brother, or sister) who has had onset of ischemic heart disease before the age of 50 years.
  • High risk of developing a myocardial infarction or coronary death.
  • History of intravenous drug abuse (within the last 12 months).
  • Known allergy to egg or aminoglycoside (gentamicin).
  • History of anaphylaxis or severe allergic reaction.
  • Subjects undergoing treatment for tuberculosis infection or disease.
  • Chronic administration of systemic immuno-suppressants.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
581 participants (actual)

Study arms

  • Experimental
    Healthy subjects

    Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)

    Biological: IMVAMUNE (MVA-BN)

  • Experimental
    HIV-infected, vaccinia-naive

    Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)

    Biological: IMVAMUNE (MVA-BN)

  • Experimental
    HIV-infected, vaccinia-experienced

    Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)

    Biological: IMVAMUNE (MVA-BN)

Interventions

  • 2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous

    Also known as: IMVANEX

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events

    Incidence, relationship and intensity of any Serious Adverse Event (SAE)

    Time frame: within 32 weeks

Secondary outcomes

  1. Related Grade >=3 Adverse Events

    Incidence of any Grade 3 or higher adverse drug reaction (missing, unknown, not evaluable, possibly, probably, or definitely related) to the study vaccine

    Time frame: within 29 days after any vaccination

  2. Solicited Local Adverse Events

    Incidence and intensity of solicited local AEs (pain, erythema, swelling). Percentages based on subjects with at least one completed diary card.

    Time frame: within 8 days after any vaccination

  3. Solicited General Adverse Events

    Incidence of solicited general AEs (increased body temperature, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.

    Time frame: within 8 days after any vaccination

  4. Unsolicited Adverse Events: Incidence

    Incidence of any unsolicited adverse events

    Time frame: within 29 days after any vaccination

  5. Unsolicited Adverse Events: Intensity

    Occurrence of unsolicited adverse events by Intensity

    Time frame: within 29 days after any vaccination

  6. Unsolicited Adverse Events: Relationship to Vaccination

    Occurrence of unsolicited adverse events by relationship to study vaccine

    Time frame: within 29 days after any vaccination

  7. CD4+ T-cell Counts

    Median CD4+ T-cell counts over time

    Time frame: within 32 weeks

  8. CD8+ T-cell Counts

    Median CD8+ T-cell counts over time

    Time frame: within 32 weeks

  9. Viral Load

    Viral load (HIV-1 RNA levels) over time

    Time frame: within 32 weeks

  10. PRNT Seroconversion Rate

    Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

    Time frame: within 32 weeks

  11. PRNT GMT

    Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.

    Time frame: within 32 weeks

  12. ELISA Seroconversion Rate

    Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

    Time frame: within 32 weeks

  13. ELISA GMT

    Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.

    Time frame: within 32 weeks

  14. ELISPOT IFN-γ: Response Rate

    Response rate based on number of subjects with response in an interferon gamma (IFN-γ) ELISPOT assay. Response is defined as the appearance of a signal in subjects that had no signal at Baseline or a relative increase by a factor of ≥1.7 compared to Baseline in subjects that had a signal at Baseline. Percentages based on number of subjects with data available.

    Time frame: within 32 weeks

  15. ELISPOT IFN-γ: SFU

    Median number of interferon gamma (IFN-γ) secreting peripheral blood mononuclear cells (PBMC) in response to stimulation with MVA-BN detected by ELISPOT assay.

    Time frame: within 32 weeks

07

Results

Posted Jan 3, 2019

Participant flow

Participant flow — Overall Study
MilestoneHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Started883529132
Completed873288127
Not completed12415
Withdrew: Withdrawal by subject0501
Withdrew: Subject unwilling/unable to comply0602
Withdrew: Adverse event1001
Withdrew: Physician decision0100
Withdrew: Other reason01211

Outcome measures

PrimarySerious Adverse Events

Incidence, relationship and intensity of any Serious Adverse Event (SAE)

Time frame:
within 32 weeks
Reported as:
Count of participants · Participants
Serious Adverse Events
ParticipantsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Any SAE01706
Any SAE with intensity >= Grade 301505
Any SAE assessed as related to vaccine0100
SecondaryRelated Grade >=3 Adverse Events

Incidence of any Grade 3 or higher adverse drug reaction (missing, unknown, not evaluable, possibly, probably, or definitely related) to the study vaccine

Time frame:
within 29 days after any vaccination
Reported as:
Count of participants · Participants
Related Grade >=3 Adverse Events
ParticipantsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Related Grade >=3 Adverse Events72605
SecondarySolicited Local Adverse Events

Incidence and intensity of solicited local AEs (pain, erythema, swelling). Percentages based on subjects with at least one completed diary card.

Time frame:
within 8 days after any vaccination
Reported as:
Count of participants · Participants
Solicited Local Adverse Events
ParticipantsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Pain: Any79246779
Pain: Grade >=392814
Erythema: Any68160761
Erythema: Grade >=32100
Swelling: Any56139652
Swelling: Grade >=31100
SecondarySolicited General Adverse Events

Incidence of solicited general AEs (increased body temperature, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.

Time frame:
within 8 days after any vaccination
Reported as:
Count of participants · Participants
Solicited General Adverse Events
ParticipantsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Increased body temperature: Any926115
Increased body temperature: Related517111
Increased body temperature: Grade >=30200
Headache: Any40117129
Headache: Related2986017
Headache: Grade >=351105
Myalgia: Any30122135
Myalgia: Related28100126
Myalgia: Grade >=341103
Chills: Any1258011
Chills: Related64207
Chills: Grade >=30301
Nausea: Any1552022
Nausea: Related1242012
Nausea: Grade >=33704
Fatigue: Any28108240
Fatigue: Related2284129
Fatigue: Grade >=321103
SecondaryUnsolicited Adverse Events: Incidence

Incidence of any unsolicited adverse events

Time frame:
within 29 days after any vaccination
Reported as:
Count of participants · Participants
Unsolicited Adverse Events: Incidence
ParticipantsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Unsolicited Adverse Events: Incidence59236373
SecondaryUnsolicited Adverse Events: Intensity

Occurrence of unsolicited adverse events by Intensity

Time frame:
within 29 days after any vaccination
Reported as:
Number · events
Unsolicited Adverse Events: Intensity
eventsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Total1495906175
Grade 11134103134
Grade 232143228
Grade 3434113
Grade 40300
Missing0000
SecondaryUnsolicited Adverse Events: Relationship to Vaccination

Occurrence of unsolicited adverse events by relationship to study vaccine

Time frame:
within 29 days after any vaccination
Reported as:
Number · events
Unsolicited Adverse Events: Relationship to Vaccination
eventsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Unrelated/None45236087
Unlikely40167142
Possible22109123
Probable1645112
Definite2631311
Missing0200
Total1495906175
SecondaryCD4+ T-cell Counts

Median CD4+ T-cell counts over time

Time frame:
within 32 weeks
Reported as:
Median · CD4 count (cells/µL)
CD4+ T-cell Counts
CD4 count (cells/µL)HIV naïveHIV Experienced
Week 0445.0 (156 to 1108)456.0 (186 to 922)
Week 1434.5 (147 to 2029)455.0 (136 to 1107)
Week 6438.5 (125 to 1045)447.0 (213 to 1081)
Week 32403.5 (138 to 1056)435.0 (273 to 762)
SecondaryCD8+ T-cell Counts

Median CD8+ T-cell counts over time

Time frame:
within 32 weeks
Reported as:
Median · CD8 count (cells/µL)
CD8+ T-cell Counts
CD8 count (cells/µL)HIV naïveHIV Experienced
Week 0771.0 (62 to 3210)877.5 (188 to 1914)
Week 1779.0 (208 to 3449)848.0 (219 to 2066)
Week 6749.0 (177 to 3238)798.5 (229 to 2319)
Week 32834.0 (196 to 2457)729.0 (245 to 1870)
SecondaryViral Load

Viral load (HIV-1 RNA levels) over time

Time frame:
within 32 weeks
Reported as:
Count of participants · Participants
Viral Load
ParticipantsHIV naïveHIV Experienced
Week 0 — Missing135
Week 0 — <400262112
Week 0 — 400 - <1000113
Week 0 — 1000 - <10000426
Week 0 — >=10000235
Week 1 — Missing157
Week 1 — <400257113
Week 1 — 400 - <1000132
Week 1 — 1000 - <10000445
Week 1 — >=10000224
Week 6 — Missing3110
Week 6 — <400240105
Week 6 — 400 - <1000183
Week 6 — 1000 - <10000416
Week 6 — >=10000217
Week 32 — Missing275108
Week 32 — <4005922
Week 32 — 400 - <100050
Week 32 — 1000 - <1000041
Week 32 — >=1000080
SecondaryPRNT Seroconversion Rate

Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

Time frame:
within 32 weeks
Reported as:
Number · percentage of subjects
PRNT Seroconversion Rate
percentage of subjectsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Week 15.3 (1.1 to 14.6)14.5 (10.3 to 19.6)60.0 (14.7 to 94.7)45.1 (34.6 to 55.8)
Week 417.5 (8.7 to 29.9)21.6 (16.6 to 27.3)60.0 (14.7 to 94.7)62.6 (51.9 to 72.6)
Week 678.9 (66.1 to 88.6)58.1 (51.6 to 64.4)80.0 (28.4 to 99.5)76.9 (66.9 to 85.1)
Week 878.9 (66.1 to 88.6)52.7 (46.2 to 59.1)80.0 (28.4 to 99.5)78.0 (68.1 to 86.0)
Week 3216.7 (5.6 to 34.7)12.5 (5.2 to 24.1)60.0 (14.7 to 94.7)64.7 (38.3 to 85.8)
SecondaryPRNT GMT

Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.

Time frame:
within 32 weeks
Reported as:
Geometric mean · Titer
PRNT GMT
TiterHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Week 01.3 (1.0 to 1.8)2.0 (1.6 to 2.4)12.0 (0.7 to 205.6)5.5 (3.6 to 8.4)
Week 11.6 (1.1 to 2.4)2.9 (2.2 to 3.7)108.9 (2.9 to 4150.0)20.5 (12.6 to 33.4)
Week 42.1 (1.3 to 3.3)3.7 (2.8 to 4.9)100.2 (2.7 to 3721.7)42.3 (26.9 to 66.4)
Week 620.8 (12.3 to 35.3)13.0 (9.6 to 17.5)354.5 (66.2 to 1899.2)88.9 (59.2 to 133.5)
Week 814.8 (9.2 to 24.0)9.7 (7.2 to 12.9)171.2 (62.2 to 470.9)76.1 (52.0 to 111.4)
Week 322.8 (1.2 to 6.3)3.3 (2.0 to 5.6)58.0 (11.1 to 303.2)53.1 (27.2 to 103.7)
SecondaryELISA Seroconversion Rate

Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

Time frame:
within 32 weeks
Reported as:
Number · percentage of subjects
ELISA Seroconversion Rate
percentage of subjectsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Week 124.6 (14.1 to 37.8)29.5 (23.8 to 35.7)80.0 (28.4 to 99.5)58.2 (47.4 to 68.5)
Week 480.7 (68.1 to 90.0)69.3 (63.1 to 75.1)100.0 (47.8 to 100.0)79.1 (69.3 to 86.9)
Week 698.2 (90.6 to 100.0)97.1 (94.1 to 98.8)100.0 (47.8 to 100.0)94.5 (87.6 to 98.2)
Week 896.5 (87.9 to 99.6)92.1 (88.0 to 95.2)100.0 (47.8 to 100.0)90.1 (82.1 to 95.4)
Week 3266.7 (47.2 to 82.7)46.4 (33.0 to 60.3)60.0 (14.7 to 94.7)76.5 (50.1 to 93.2)
SecondaryELISA GMT

Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.

Time frame:
within 32 weeks
Reported as:
Geometric mean · Titer
ELISA GMT
TiterHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Week 01.9 (1.2 to 3.0)4.6 (3.5 to 6.0)37.1 (2.6 to 529.8)33.3 (21.5 to 51.5)
Week 13.7 (2.1 to 6.5)9.4 (6.9 to 12.8)260.6 (36.6 to 1858.0)89.9 (56.0 to 144.3)
Week 456.2 (34.9 to 90.5)46.6 (35.7 to 60.9)461.1 (63.8 to 3332.9)220.1 (154.5 to 313.5)
Week 6526.2 (400.2 to 691.8)299.8 (253.4 to 354.7)612.9 (107.6 to 3490.5)588.4 (463.6 to 746.7)
Week 8312.9 (235.5 to 415.8)175.5 (143.6 to 214.6)403.4 (77.0 to 2112.0)453.1 (370.7 to 553.7)
Week 3232.1 (14.7 to 70.1)24.3 (12.7 to 46.5)89.5 (3.6 to 2230.7)203.9 (152.7 to 272.4)
SecondaryELISPOT IFN-γ: Response Rate

Response rate based on number of subjects with response in an interferon gamma (IFN-γ) ELISPOT assay. Response is defined as the appearance of a signal in subjects that had no signal at Baseline or a relative increase by a factor of ≥1.7 compared to Baseline in subjects that had a signal at Baseline. Percentages based on number of subjects with data available.

Time frame:
within 32 weeks
Reported as:
Number · percentage of subjects
ELISPOT IFN-γ: Response Rate
percentage of subjectsHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Week 139.1 (19.7 to 61.5)28.6 (14.6 to 46.3)0.0 (0.0 to 70.8)26.5 (16.5 to 38.6)
Week 439.1 (19.7 to 61.5)20.0 (8.4 to 36.9)33.3 (0.8 to 90.6)29.4 (19.0 to 41.7)
Week 647.8 (26.8 to 69.4)40.0 (23.9 to 57.9)0.0 (0.0 to 70.8)29.4 (19.0 to 41.7)
Week 830.4 (13.2 to 52.9)25.7 (12.5 to 43.3)0.0 (0.0 to 70.8)29.4 (19.0 to 41.7)
Week 3252.4 (29.8 to 74.3)36.8 (16.3 to 61.6)50.0 (1.3 to 98.7)23.1 (5.0 to 53.8)
SecondaryELISPOT IFN-γ: SFU

Median number of interferon gamma (IFN-γ) secreting peripheral blood mononuclear cells (PBMC) in response to stimulation with MVA-BN detected by ELISPOT assay.

Time frame:
within 32 weeks
Reported as:
Median · Spot Forming Units / 10^6 PBMC
ELISPOT IFN-γ: SFU
Spot Forming Units / 10^6 PBMCHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Week 00.0 (0 to 230)0.0 (0 to 239)155.0 (88 to 542)0.0 (0 to 233)
Week 187.0 (0 to 497)0.0 (0 to 806)71.0 (0 to 322)0.0 (0 to 375)
Week 493.0 (0 to 501)0.0 (0 to 371)569.0 (100 to 1143)0.0 (0 to 603)
Week 699.0 (0 to 754)72.0 (0 to 822)54.0 (0 to 751)57.5 (0 to 570)
Week 80.0 (0 to 599)0.0 (0 to 505)71.0 (0 to 96)53.0 (0 to 550)
Week 3271.0 (0 to 942)73.0 (0 to 370)596.0 (454 to 738)0.0 (0 to 365)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy naïve0/88 (0%)0/88 (0%)51/88 (58%)
HIV naïve1/351 (0.3%)17/351 (4.8%)172/351 (49%)
Healthy Experienced0/9 (0%)0/9 (0%)3/9 (33.3%)
HIV Experienced0/131 (0%)6/131 (4.6%)45/131 (34.4%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
GastroenteritisInfections and infestations0/880/3510/92/131
DiarrhoeaGastrointestinal disorders0/880/3510/91/131
PancreatitisGastrointestinal disorders0/880/3510/91/131
PneumothoraxRespiratory, thoracic and mediastinal disorders0/880/3510/91/131
Peripheral arterial occlusive diseaseVascular disorders0/880/3510/91/131
GangreneInfections and infestations0/880/3510/91/131
OverdoseInjury, poisoning and procedural complications0/882/3510/90/131
PneumoniaInfections and infestations0/882/3510/90/131
NeurosyphilisInfections and infestations0/881/3510/90/131
LymphadenopathyBlood and lymphatic system disorders0/881/3510/90/131
Most frequent other events
Showing 10 of 31
Most frequent other events
EventHealthy naïveHIV naïveHealthy ExperiencedHIV Experienced
Injection site pruritisGeneral disorders22/8866/3512/922/131
Injection site noduleGeneral disorders3/886/3511/90/131
PyrexiaGeneral disorders0/888/3511/90/131
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders4/8812/3511/95/131
Troponin I increasedInvestigations9/8831/3510/97/131
SinusitisInfections and infestations5/886/3510/90/131
HeadacheNervous system disorders5/888/3510/93/131
DiarrhoeaGastrointestinal disorders2/8814/3510/96/131
CoughRespiratory, thoracic and mediastinal disorders0/8816/3510/93/131
VomitingGastrointestinal disorders4/881/3510/91/131

Baseline characteristics

Full Analysis Set

Age, Continuous
Age, Continuous(years)Healthy naïveHIV naïveHealthy ExperiencedHIV ExperiencedTotal
Mean28.9 ± 7.1436.8 ± 7.9845.6 ± 8.8844.6 ± 5.1337.5 ± 8.80
Sex: Female, Male
Sex: Female, Male(Participants)Healthy naïveHIV naïveHealthy ExperiencedHIV ExperiencedTotal
Female5064421139
Male382875110440
Region of Enrollment
Region of Enrollment(participants)Healthy naïveHIV naïveHealthy ExperiencedHIV ExperiencedTotal
Puerto Rico0270734
United States883249124545
08

Study locations

36 sites
  • Alabama Vaccine Research Clinic; University of Alabama at Birmingham
    Birmingham, Alabama 35294-2050, United States
  • Health for Life Clinic, PLLC
    Little Rock, Arkansas 72207, United States
  • Providence Clinical Research
    Burbank, California 91505, United States
  • Northern California Research
    Carmichael, California 95608, United States
  • CSI Clinical Trials, Inc.
    Fountain Valley, California 92708, United States
  • AltaMed Health Services
    Los Angeles, California 90022, United States
  • Alta Bates Summit Medical Center, East Bay AIDS Center
    Oakland, California 94609, United States
  • Benchmark Clinical Research
    San Francisco, California 94102, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Consultive Medicine
    Daytona Beach, Florida 32117, United States
  • Northpoint Medical, PA
    Fort Lauderdale, Florida 33308, United States
  • The Kinder Medical Group
    Miami, Florida 33133, United States
  • Infectious Diseases of NW Florida
    Pensacola, Florida 32504, United States
  • Palm Beach Center
    West Palm Beach, Florida 33409, United States
  • Atlanta ID Group
    Atlanta, Georgia 30309, United States
  • The CORE Center
    Chicago, Illinois 60612, United States
  • Northstar Medical Center
    Chicago, Illinois 60657, United States
  • Indiana University School of Medicine; Division of Infectious Disease
    Indianapolis, Indiana 46202-2859, United States
  • University of Iowa, Division of Infectious Diseases
    Iowa City, Iowa 52242, United States
  • Nemechek Health Renewal
    Kansas City, Missouri 64111, United States
  • St. Louis University, Center for Vaccine Dev.
    Saint Louis, Missouri 63104, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-5130, United States
  • Immuniodeficiency Clinic, ECMC
    Buffalo, New York 14260, United States
  • Universtity of Rochester School of Medicine
    Rochester, New York 14642, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104-6073, United States
  • Clinical Trials Research Services
    Pittsburgh, Pennsylvania 15206, United States
  • Brown Medical School
    Providence, Rhode Island 02906, United States
  • University of South Carolina
    Columbia, South Carolina 29203, United States
  • Vanderbilt University, AIDS Clinical Trials Center
    Nashville, Tennessee 37203, United States
  • Nicholaos C. Bellos, MD PA
    Dallas, Texas 75204, United States
  • Valley AIDS Council
    Harlingen, Texas 78550, United States
  • Diversified Medical Practices
    Houston, Texas 77027, United States
  • Clinical Research P.R., Inc.
    San Juan, 00909, Puerto Rico
  • Maternal Infant Studies Center (CEMI)
    San Juan, 00936-5067, Puerto Rico
09

References and documents

Publications

  • Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, Wagner E, von Krempelhuber A, Virgin G, Meyer TP, Muller J, Badeker N, Grunert R, Young P, Rosch S, Maclennan J, Arndtz-Wiedemann N, Chaplin P. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infect Dis. 2015 May 5;2(2):ofv040. doi: 10.1093/ofid/ofv040. eCollection 2015 Apr. Erratum In: Open Forum Infect Dis. 2016 Feb 18;3(1):ofv183. doi: 10.1093/ofid/ofv183. PubMed 26380340 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Mar 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 9 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2006
First posted
Apr 21, 2006
Start
Jun 2006
Primary completionActual
Mar 2009
CompletionActual
Oct 2009
Results first posted
Jan 3, 2019
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00316589
Lead sponsor
Bavarian Nordic
Responsible party
Sponsor
First posted
Apr 21, 2006
Start date
Jun 2006
Primary completion
Mar 2009
Completion
Oct 2009
Results posted
Jan 3, 2019
Last update
Jan 3, 2019

Study contacts

Edgar Turner Overton, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-BN smallpox vaccine

Start the discussion